The prevalence of obesity is burgeoning in the United States. As a result, obesity-related metabolic disorders that confer increased CVD risk, including diabetes, dyslipidemia, and hypertension are reaching epidemic proportions. Susceptibility to the adverse metabolic consequences of obesity varies widely in the population: modest increases in adiposity lead to severe metabolic decompensation in some individuals, whereas others maintain a normal metabolic profile despite severe obesity. The overall goal of this project is to identify specific genetic mechanisms that account for the variability of metabolic responses to excess body weight and to evaluate the therapeutic potential of agents that target these mechanisms. The study includes three complementary strategies: First, we will sequence selected candidate genes in a large, multi-ethnic population (The Dallas Heart Study) in which each participant has undergone extensive metabolic characterization and relate the phenotypes to selected genotypes. Our focus will be on two groups of genes: 1) genes encoding circulating proteins that carry metabolic signals between the brain, liver, adipose tissue, and intestine ('metabokines'), and 2) genes encoding selected transcriptional regulatory molecules than respond to metabolic signals ('cellular metabolic regulators'). Included in these studies are genes being mechanistically interrogated in Projects 1-3. Second, we will use genome-wide methods as unbiased approaches toward the discovery of new genes and sequence variants that contribute to inter-individual differences in the metabolic responses to obesity. Third, we will collaborate with investigators in Projects 4 &5 and perform detailed studies of glucose and lipid metabolism in both mice and humans to elucidate the mechanistic basis for genetic variation in susceptibility to the adverse metabolic consequences of obesity. This ambitious, interdisciplinary program leverages our established strengths in pairing careful phenotypic characterization with comprehensive genetic analyses in humans to discover new genes and sequence variations contributing to metabolic traits. In addition we have established collaborations that provide access to large, prospective population studies in which the effects of genetic sequence variants can be rigorously validated. These collaborations, together with the complementary expertise of our collaborators in Projects 1-5 greatly expand the scientific scope of our studies and increases our potential to identify new therapeutic targets and approaches to prevent and treat the adverse metabolic consequences of obesity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Linked Research project Grant (RL1)
Project #
5RL1HL092550-05
Application #
8117811
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Applebaum-Bowden, Deborah
Project Start
2007-09-30
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$715,920
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Fu, Ting; Guan, YangYang; Xu, Junjie et al. (2017) APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo. Biochim Biophys Acta 1862:883-889
Kozlitina, Julia; Smagris, Eriks; Stender, Stefan et al. (2014) Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46:352-6
Wang, Yan; Quagliarini, Fabiana; Gusarova, Viktoria et al. (2013) Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A 110:16109-14
Cohen, Jonathan C (2013) Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids. J Clin Lipidol 7:S1-5
Wang, Yan; Huang, Yongcheng; Hobbs, Helen H et al. (2012) Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res 53:1932-43
Li, Yiling; Xing, Chao; Cohen, Jonathan C et al. (2012) Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology 55:327-8
Molho-Pessach, Vered; Rios, Jonathan J; Xing, Chao et al. (2012) Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology. Hepatology 55:1139-45
Quagliarini, Fabiana; Wang, Yan; Kozlitina, Julia et al. (2012) Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A 109:19751-6
Liu, Dajiang J; Leal, Suzanne M (2012) A flexible likelihood framework for detecting associations with secondary phenotypes in genetic studies using selected samples: application to sequence data. Eur J Hum Genet 20:449-56
Liu, Dajiang J; Leal, Suzanne M (2012) Estimating genetic effects and quantifying missing heritability explained by identified rare-variant associations. Am J Hum Genet 91:585-96

Showing the most recent 10 out of 29 publications